Pushing the forefront of therapeutic antibody discovery.
Ligand Pharmaceuticals’ OmniAb provides the industry’s only offering with four transgenic animal species, strategically built to optimally harness the unparalleled power of Biological Intelligence. Beginning with OmniRat® in 2012, this suite of animal technologies has expanded over the years with the addition of OmniChicken® in 2016, OmniClic® in 2019, and OmniTaur™ in 2020.
In 2020, OmniAb’s offerings also broadened to include antigen design and other technologies that supplement the animal offerings. As a leader in transgenic animal technology, we are committed to providing technologies that enable and enhance the discovery of therapeutic antibodies